Drug Trial Radar · NCT06926868
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Sep 11, 2025
Primary completion
Mar 13, 2028
Study completion May 15, 2030
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- SystImmune Inc.
- First posted
- Apr 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen receptor (ER)-low, human epidermal growth factor receptor 2 (HER2)-negative BC patients who are not candidates for anti-PD(L)1 therapy and endocrine therapies.
Conditions
- Breast Neoplasms
Interventions
Iza-brenDrug
Specified dose on specified days
Nab-paclitaxelDrug
Specified dose on specified days
PaclitaxelDrug
Specified dose on specified days
CapecitabineDrug
Specified dose on specified days
CarboplatinDrug
Specified dose on specified days
GemcitabineDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: Approximately 22 months from first participant randomization in Phase 3
- Recommended Phase 3 Dose (RP3D) of BMS-986507Time frame: Approximately 13 months from first participant randomization in Phase 2
Locations
296 sites in 28 countries. Site status is shown where the registry gives one.
Local Institution - 0303
Hot Springs, Arkansas · Not yet recruiting
Local Institution - 0307
Cerritos, California · Withdrawn
Local Institution - 0308
Cerritos, California · Withdrawn
Local Institution - 0309
Cerritos, California · Withdrawn
Local Institution - 0328
Cerritos, California · Active not recruiting
Local Institution - 0311
Long Beach, California · Withdrawn
Local Institution - 0290
Los Angeles, California · Completed
Local Institution - 0283
Los Angeles, California · Completed
Local Institution - 0353
Newport Beach, California · Completed
Local Institution - 0358
Stanford, California · Withdrawn
Local Institution - 0289
Aurora, Colorado · Not yet recruiting
Local Institution - 0367
Denver, Colorado · Active not recruiting
Local Institution - 0304
Newark, Delaware · Completed
Local Institution - 0296
Pembroke Pines, Florida · Withdrawn
Local Institution - 0294
Atlanta, Georgia · Completed
Local Institution - 0357
Atlanta, Georgia · Completed
Local Institution - 0278
Chicago, Illinois · Withdrawn
Local Institution - 0280
Chicago, Illinois · Not yet recruiting
Local Institution - 0275
Decatur, Illinois · Completed
Local Institution - 0324
O'Fallon, Illinois · Withdrawn
Local Institution - 0286
Covington, Louisiana · Completed
Local Institution - 1035
Baltimore, Maryland · Withdrawn
Local Institution - 0288
Boston, Massachusetts · Completed
Local Institution - 0287
Boston, Massachusetts · Active not recruiting
Local Institution - 0359
Detroit, Michigan · Completed
Local Institution - 0313
Maple Grove, Minnesota · Completed
Local Institution - 0372
Minneapolis, Minnesota · Withdrawn
Local Institution - 0284
Kansas City, Missouri · Completed
Local Institution - 0312
New York, New York · Withdrawn
Local Institution - 0279
New York, New York · Completed
Local Institution - 1037
Syracuse, New York · Withdrawn
Local Institution - 0295
Westbury, New York · Completed
Local Institution - 0285
White Plains, New York · Completed
Local Institution - 0276
Durham, North Carolina · Completed
Local Institution - 0316
Eugene, Oregon · Completed
Local Institution - 0356
Allentown, Pennsylvania · Active not recruiting
Local Institution - 0310
Philadelphia, Pennsylvania · Completed
Local Institution - 0360
Pittsburgh, Pennsylvania · Withdrawn
Local Institution - 0281
Greenville, South Carolina · Completed
Local Institution - 0315
Austin, Texas · Completed
Showing 40 of 296 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.